TY - JOUR
T1 - Current and emerging therapies in unresectable and recurrent gastric cancer
AU - Jou, Erin
AU - Rajdev, Lakshmi
N1 - Publisher Copyright:
© 2016 Baishideng Publishing Group Inc.
PY - 2016/5/28
Y1 - 2016/5/28
N2 - Gastric cancer is one of the most lethal cancers worldwide despite many advances and options in therapy. As it is often diagnosed at an advanced stage, prognosis is poor with a median overall survival of less than twelve months. Chemotherapy remains the mainstay of treatment for these patients but it confers only a moderate survival advantage. There remains a need for new targeted treatment options and a way to better define patient populations who will benefit from these agents. In the past few years, there has been a better understanding of the biology, molecular profiling, and heterogeneity of gastric cancer. Our increased knowledge has led to the identification of gastric cancer subtypes and to the development of new targeted therapeutic agents. There are now two new targeted agents, trastuzumab and ramucirumab, that have recently been approved for the treatment of advanced and metastatic gastric cancer. There are also many other actively investigated targets, including epidermal growth factor receptor, the phosphatadylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathway, c-Met, poly ADP-ribose polymerase, and immune checkpoint inhibition. In this review, we discuss the current management of advanced gastric cancer as well as emerging targeted therapies and immunotherapy.
AB - Gastric cancer is one of the most lethal cancers worldwide despite many advances and options in therapy. As it is often diagnosed at an advanced stage, prognosis is poor with a median overall survival of less than twelve months. Chemotherapy remains the mainstay of treatment for these patients but it confers only a moderate survival advantage. There remains a need for new targeted treatment options and a way to better define patient populations who will benefit from these agents. In the past few years, there has been a better understanding of the biology, molecular profiling, and heterogeneity of gastric cancer. Our increased knowledge has led to the identification of gastric cancer subtypes and to the development of new targeted therapeutic agents. There are now two new targeted agents, trastuzumab and ramucirumab, that have recently been approved for the treatment of advanced and metastatic gastric cancer. There are also many other actively investigated targets, including epidermal growth factor receptor, the phosphatadylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathway, c-Met, poly ADP-ribose polymerase, and immune checkpoint inhibition. In this review, we discuss the current management of advanced gastric cancer as well as emerging targeted therapies and immunotherapy.
KW - Advanced gastric cancer
KW - Human epidermal growth factor receptor type 2
KW - Immunotherapy
KW - Targeted therapy
KW - Vascular endothelial growth factor receptor
UR - http://www.scopus.com/inward/record.url?scp=84978770179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978770179&partnerID=8YFLogxK
U2 - 10.3748/wjg.v22.i20.4812
DO - 10.3748/wjg.v22.i20.4812
M3 - Review article
C2 - 27239108
AN - SCOPUS:84978770179
SN - 1007-9327
VL - 22
SP - 4812
EP - 4823
JO - World Journal of Gastroenterology
JF - World Journal of Gastroenterology
IS - 20
ER -